Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.03B P/E - EPS this Y -4.90% Ern Qtrly Grth -
Income 15.47M Forward P/E 12.12 EPS next Y 11.80% 50D Avg Chg 1.00%
Sales 486.82M PEG 6.59 EPS past 5Y -8.35% 200D Avg Chg 19.00%
Dividend N/A Price/Book 2.69 EPS next 5Y 2.20% 52W High Chg -6.00%
Recommedations 1.80 Quick Ratio 2.63 Shares Outstanding 20.98M 52W Low Chg 67.00%
Insider Own 11.20% ROA 3.72% Shares Float 15.09M Beta 0.80
Inst Own 75.94% ROE 4.72% Shares Shorted/Prior 213.52K/261.60K Price 51.13
Gross Margin 62.71% Profit Margin 3.86% Avg. Volume 142,772 Target Price 79.80
Oper. Margin 6.62% Earnings Date May 10 Volume 67,516 Change 0.69%
About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANI Pharmaceuticals, Inc. News
ANIP Chatroom

User Image insiderbuyingselling Posted - 4 days ago

$ANIP new insider selling: 27232 shares. http://insiderbuyingselling.com/?t=ANIP

User Image Stock_Titan Posted - 1 week ago

$ANIP ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET https://www.stocktitan.net/news/ANIP/ani-pharmaceuticals-to-discuss-first-quarter-2024-financial-results-orz27m8hih1d.html

User Image insiderbuyingselling Posted - 1 week ago

$ANIP new insider selling: 250 shares. http://insiderbuyingselling.com/?t=ANIP

User Image DonCorleone77 Posted - 2 weeks ago

$ANIP ANI Pharmaceuticals announces launch of Baclofen Oral Suspension ANI Pharmaceuticals announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug Fleqsuvy. U.S. annual sales for Baclofen Oral Suspension total approximately $39M, according to IQVIA data.

User Image Stock_Titan Posted - 2 weeks ago

$ANIP ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension https://www.stocktitan.net/news/ANIP/ani-pharmaceuticals-announces-the-launch-of-baclofen-oral-sg3uyegh61f6.html

User Image Stock_Titan Posted - 3 weeks ago

$ANIP ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis https://www.stocktitan.net/news/ANIP/ani-pharmaceuticals-recognizes-sarcoidosis-awareness-month-and-zgqw09hoet4s.html

User Image AnchorsAweigh Posted - 3 weeks ago

@Doozio ANIK $ANIP

User Image Stock_Titan Posted - 3 weeks ago

$ANIP ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium https://www.stocktitan.net/news/ANIP/ani-pharmaceuticals-to-participate-at-the-piper-sandler-spring-t866lmi3meyi.html

User Image Turkif2020 Posted - 3 weeks ago

$ANIP 🙃 62 57 Drop Nomore over 69$ Sl 70 2 days

User Image Stocktwits Posted - 03/27/24

$ANIP Place your bets...

User Image DonCorleone77 Posted - 03/27/24

$ANIP Let's see if this helps push her to new highs: ANI Pharmaceuticals announces launch of Levofloxacin Oral Solution ANI Pharmaceuticals announced the launch of Levofloxacin Oral Solution, a generic version of the Reference Listed Drug Levaquin. The current annual U.S. market for Levofloxacin Oral Solution is approximately $7.1M, according to latest estimates from IQVIA/IMS Health, a leading healthcare data and analytics provider.

User Image Stock_Titan Posted - 03/27/24

$ANIP ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP https://www.stocktitan.net/news/ANIP/ani-pharmaceuticals-announces-the-launch-of-levofloxacin-oral-n98v7p65fds5.html

User Image Dy2ski Posted - 1 month ago

$ANIP Pushing nicely towards a 52-week high...

User Image DonCorleone77 Posted - 1 month ago

@MaverikIT @net0trader @Wigglyick @Cash4freedom @RonIsWrong @Im_not_Mr_Lebowski @IsabellaDC RIW, I am in $ANIP and $MDWD. The latter announced earnings this morning. Do you follow either? Been watching ANIP for some times and someone recently made me aware of MDWD. Hoping you might have some more insights.

User Image DonCorleone77 Posted - 1 month ago

$ANIP ANI Pharmaceuticals initiated with an Overweight at Capital One Capital One initiated coverage of ANI Pharmaceuticals with an Overweight rating and $80 price target.

User Image insiderbuyingselling Posted - 1 month ago

$ANIP new insider selling: 20000 shares. http://insiderbuyingselling.com/?t=ANIP

User Image grgurovich Posted - 1 month ago

User Image insiderbuyingselling Posted - 1 month ago

$ANIP new insider selling: 7787 shares. http://insiderbuyingselling.com/?t=ANIP

User Image insiderbuyingselling Posted - 1 month ago

$ANIP new insider selling: 45257 shares. http://insiderbuyingselling.com/?t=ANIP

User Image insiderbuyingselling Posted - 1 month ago

$ANIP new insider selling: 40000 shares. http://insiderbuyingselling.com/?t=ANIP

User Image Doozio Posted - 1 month ago

$ANIP 🧠⏰ is…… n it’s still soooo early.

User Image SilverBull925 Posted - 1 month ago

$ANIP

User Image SilverBull925 Posted - 1 month ago

$ANIP ye ye

User Image DonCorleone77 Posted - 1 month ago

$ANIP ANI Pharmaceuticals price target raised to $77 from $70 at Guggenheim Guggenheim raised the firm's price target on ANI Pharmaceuticals to $77 from $70 and keeps a Buy rating on the shares after the company "once again" delivered record quarterly cortrophin gel net revenues "well above" the firm's recently increased expectations. In addition, the company's initial FY24 guidance "appears reasonable and encouraging to us, with plenty of room for upside," the analyst tells investors.

User Image DonCorleone77 Posted - 1 month ago

$ANIP From an Insider Monkey article this evening entitled: "11 Best Small Cap Pharma Stocks to Invest In" Number 8: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Number of Hedge Fund Investors In Q4 2023: 19 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) provides a diversified set of medicines and pharmaceutical products such as hormonal treatments, steroids, and others. Its shares have performed well over the past 12 months, by having gained 41% and undoubtedly helped by earnings beats in all four latest quarters. During last year's final quarter, 19 out of the 933 hedge funds surveyed by Insider Monkey were the firm's shareholders. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)'s biggest stakeholder in our database is David Rosen's Rubric Capital Management as it owns 1.1 million shares that are worth $62 million.

User Image DonCorleone77 Posted - 1 month ago

$ANIP Watching this one: ANI Pharmaceuticals price target raised to $83 from $73 at H.C. Wainwright H.C. Wainwright raised the firm's price target on ANI Pharmaceuticals to $83 from $73 and keeps a Buy rating on the shares following the Q4 beat. The firm says the company has momentum across its rare disease and generics units.

User Image DonCorleone77 Posted - 1 month ago

$ANIP Might be worth keeping an eye on?: ANI Pharmaceuticals price target raised to $80 from $72 at Truist Truist raised the firm's price target on ANI Pharmaceuticals to $80 from $72 and keeps a Buy rating on the shares. The company reported another strong quarter, driven by continued Cortrophin uptake and generics growth on higher volume and product launches, the analyst tells investors in a research note. The frequency of competitor disruptions have somewhat eased, though the management expects high-single to low-double digit growth for the GX segment, the firm added.

User Image _StockTrader Posted - 02/29/24

Real-Time Stock Data $ANIP Price: 68.45 Volume: 566594 Market Cap: 1403927168 PE Ratio: 15.87298 Stock data provided by: PSYC

User Image AnchorsAweigh Posted - 02/29/24

$ANIP breaking out

User Image Tlinz50 Posted - 02/29/24

$ANIP Another Beat and Raise. Great Qtr and Year! They guided to 520M-542M Revenue for 24. I believe they are still sandbagging. I think we will see guidance increased throughout the year. I project at least 575M Rev for 24.

Analyst Ratings
Guggenheim Buy Apr 23, 24
Capital One Overweight Mar 15, 24
Guggenheim Buy Mar 5, 24
HC Wainwright & Co. Buy Mar 4, 24
Truist Securities Buy Mar 1, 24
Truist Securities Buy Feb 16, 24
Guggenheim Buy Oct 19, 23
Guggenheim Buy Sep 13, 23
HC Wainwright & Co. Buy Aug 22, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Shanmugam Muthusamy HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS Jan 19 Sell 55.99 25,216 1,411,844 882,620 01/23/24
Shanmugam Muthusamy HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS Jan 16 Sell 55.35 24,784 1,371,794 907,836 01/18/24
Cook Meredith SR. VP, GENERAL COUN.. SR. VP, GENERAL COUNSEL & SEC. Jan 12 Sell 56.43 250 14,108 37,049 01/16/24
Shanmugam Muthusamy HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS Dec 15 Sell 52.51 50,000 2,625,500 932,620 12/19/23
Cook Meredith SR. VP, GENERAL COUN.. SR. VP, GENERAL COUNSEL & SEC. Dec 11 Sell 49.21 250 12,302 37,299 12/11/23
Shanmugam Muthusamy HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS Nov 17 Sell 51 13,000 663,000 982,620 11/20/23
Shanmugam Muthusamy HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS Nov 14 Sell 52.82 37,000 1,954,340 995,620 11/20/23
Davis Krista SVP, CHIEF HR OFFICE.. SVP, CHIEF HR OFFICER Nov 15 Sell 53.81 2,622 141,090 32,587 11/16/23
Gassert Chad SVP - CORP. DEV. & S.. SVP - CORP. DEV. & STRATEGY Oct 02 Sell 56.48 20,000 1,129,600 293,226 10/03/23
Shanmugam Muthusamy HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS Sep 15 Sell 61.89 50,000 3,094,500 1,082,620 09/19/23
Gassert Chad SVP - CORP. DEV. & S.. SVP - CORP. DEV. & STRATEGY Sep 01 Sell 64.70 20,000 1,294,000 313,226 09/05/23
MERIDIAN VENTURE PARTNERS II L... 10% Owner 10% Owner Aug 16 Sell 58.50 200,000 11,700,000 1,819,259 08/16/23
Shanmugam Muthusamy HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS Aug 14 Sell 61.38 50,000 3,069,000 1,182,620 08/16/23
Pera Antonio R Director Director Aug 14 Sell 60.37 3,000 181,110 33,627 08/15/23
Lalwani Nikhil PRESIDENT & CEO PRESIDENT & CEO Aug 11 Sell 59.44 68,282 4,058,682 353,390 08/15/23
Lalwani Nikhil PRESIDENT & CEO PRESIDENT & CEO Aug 11 Option 29 11,616 336,864 365,006 08/15/23
Gassert Chad SVP - CORP. DEV. & S.. SVP - CORP. DEV. & STRATEGY Aug 01 Sell 51.06 20,000 1,021,200 333,226 08/03/23
Shanmugam Muthusamy HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS Jul 19 Sell 51.85 23,469 1,216,868 1,232,620 07/21/23
Shanmugam Muthusamy HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS Jul 14 Sell 51.11 26,531 1,355,999 1,256,089 07/18/23
Shanmugam Muthusamy HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS Jun 20 Sell 51.69 50,000 2,584,500 1,282,620 06/23/23
Gassert Chad SVP - CORP. DEV. & S.. SVP - CORP. DEV. & STRATEGY Jun 22 Sell 51.32 20,000 1,026,400 373,226 06/23/23
Marken James G. SVP OPS & PROD DEV SVP OPS & PROD DEV Aug 12 Sell 37.42 18,066 676,030 117,642 08/16/22
Lalwani Nikhil PRESIDENT & CEO PRESIDENT & CEO Mar 21 Buy 27.6851 7,224 199,997 169,650 03/23/22
Walsh Patrick D Director Director Mar 21 Buy 27.7588 5,000 138,794 53,388 03/22/22
Gassert Chad SVP - CORP. DEV. & S.. SVP - CORP. DEV. & STRATEGY Mar 18 Buy 27.51 10,000 275,100 393,226 03/22/22
Shanmugam Muthusamy HEAD OF R&D, COO-NOV.. HEAD OF R&D, COO-NOVITIUM OPS Mar 17 Buy 27.65 10,000 276,500 5,000 03/21/22